Across TCGA pan-cancer cohorts, RPL21P112 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL21P112’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where RPL21P112 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL21P112 is over-expressed in tumor, although a few such as STAD show the opposite, repressed pattern.
COAD and STAD are the cancer types where RPL21P112 tumor–normal differential expression is most reproducible.